According to a Phase I study led by researchers at The University of Texas MD Anderson Cancer Center, published in Nature ...

Anktiva plus checkpoint inhibitor therapy demonstrated statistically significant immune restoration across two clinical ...

QUILT-3.055 is a basket trial evaluating nogapendekin alfa inbakicept across multiple solid tumor types. In the NSCLC cohort, ...

Needle-free Injection System - Stratis(R) - was used to deliver Scancell's iSCIB1+ DNA immunotherapy in combination with immune checkpoint inhibitors in the SCOPE Phase 2 trial. -- The Scancell ...

Oncologists have achieved some immune system responses in patients with pancreatic cancers using various combinations of ...

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced positive results from its ANKTIVA ...

Following four doses of Bria-OTS as a single-agent therapy, the lung metastasis completely disappeared, the company said. ・he ...

Phase 1b LANTERN clinical study is assessing tolododekin alfa, anchored IL-12 immunotherapy, in combination with anti PD-1/PD-L1 immune checkpoint blockade for treatment of non-small cell lung cancer ...

ImmunityBio recently reported positive clinical data from its ANKTIVA (nogapendekin alfa inbakicept) program in non-small ...

Vaxiion Therapeutics Announces Completion of Phase 1a Dose Escalation and Initiation of a Phase 1b Dose Expansion Study for Intralesional Administration of VAX014 in Combination with PD-1 Directed ...

Survival and safety of two year-fixed duration vs continuous immune checkpoint inhibitor therapy in advanced or metastatic NSCLC: A systematic review. This is an ASCO Meeting Abstract from the 2025 ...

Immune checkpoint molecules play a crucial role in keeping the immune system in balance and preventing an attack on the ...